Piura B, Meirovitz M, Bartfeld M, Yanai-Inbar I, Cohen Y
Department of Obstetrics and Gynecology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
J Surg Oncol. 1998 Jul;68(3):173-8. doi: 10.1002/(sici)1096-9098(199807)68:3<173::aid-jso8>3.0.co;2-2.
Peritoneal papillary serous carcinoma (PPSC) is histologically and clinically similar to stage III-IV ovarian papillary serous carcinoma (OPSC). The purpose of this study was to investigate the clinical findings, treatment, and outcome of PPSC patients compared with stage III-IV OPSC patients.
Data from the files of 15 PPSC patients and 52 stage III-IV OPSC patients who were managed at the Soroka Medical Center between January 1991 and December 1997 were evaluated.
With regard to patients' characteristics, presenting signs and symptoms, type and extent of surgery, tumor response to first-line chemotherapy, recurrence-free interval, recurrence site, tumor response to second-line chemotherapy, and serum CA-125 levels, no significant differences were observed between the PPSC patients and the stage III-IV OPSC controls. The prevailing presenting symptoms were abdominal mass and ascites. The mainstay of treatment was debulking surgery followed by adjuvant platinum-containing chemotherapy. The objective response rate to first-line chemotherapy was 80%. The actuarial 5-year survival rate for the PPSC patients and stage III-IV OPSC patients was 52.0% and 20.5%, respectively (0.05 < P < 0.1).
The clinical and surgical characteristics of patients with PPSC are similar to those of patients with stage III-IV OPSC. When treatment strategies for stage III-IV OPSC are applied to PPSC, the survival of PPSC patients may be similar or even better than that of stage III-IV OPSC patients.
腹膜乳头状浆液性癌(PPSC)在组织学和临床上与Ⅲ-Ⅳ期卵巢乳头状浆液性癌(OPSC)相似。本研究旨在调查PPSC患者与Ⅲ-Ⅳ期OPSC患者的临床特征、治疗及预后情况。
对1991年1月至1997年12月在索罗卡医疗中心接受治疗的15例PPSC患者和52例Ⅲ-Ⅳ期OPSC患者的病历资料进行评估。
在患者特征、出现的体征和症状、手术类型及范围、肿瘤对一线化疗的反应、无复发生存期、复发部位、肿瘤对二线化疗的反应以及血清CA-125水平方面,PPSC患者与Ⅲ-Ⅳ期OPSC对照患者之间未观察到显著差异。主要的出现症状为腹部肿块和腹水。治疗的主要方法是肿瘤细胞减灭术,随后进行含铂辅助化疗。一线化疗的客观缓解率为80%。PPSC患者和Ⅲ-Ⅳ期OPSC患者的精算5年生存率分别为52.0%和20.5%(0.05 < P < 0.1)。
PPSC患者的临床和手术特征与Ⅲ-Ⅳ期OPSC患者相似。当将Ⅲ-Ⅳ期OPSC的治疗策略应用于PPSC时,PPSC患者的生存率可能与Ⅲ-Ⅳ期OPSC患者相似,甚至更好。